Edgewise Therapeutics, Inc.
Company Stats
- Market Cap
- $4.4B
- as of Sep 30, 2026
- Shares Outstanding
- 108.6M
- Free Float
- 57.0%
Income Statement
- Operating Income
- -$191.4M
- Net Income
- -$167.8M
- EBITDA
- -$189.3M
Cash Flow
- Free Cash Flow
- -$144.1M
- FCF Yield
- -3.3%
- Owner FCF Yield
- -4.1%
Balance Sheet
- Cash & Equivalents
- $61.1M
Returns & Capital
- SBC, 3Y Avg
- $25.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$144.1M | — |
| FY2024 | — | -$110.3M | — |
| FY2023 | — | -$97.7M | — |
| FY2022 | — | -$58.2M | — |
| FY2021 | — | -$34.2M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
Stronger demand supports expansion as pricing diverges